Clinical Trial

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Study acronym: STING
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab. The phase 2 of the study will estimate the response to treatment.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2019-12-23; most recent amendment 2025-05-08.
Status change: Not Yet Recruiting → Recruiting 2022-09-01
Trial Details
NCT Number NCT04211675
Lead Sponsor Nationwide Children's Hospital
Conditions Relapsed Neuroblastoma, Refractory Neuroblastoma
Enrollment 31 participants
Start Date 2022-09-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-13